Analytica Laser, which assess real-world outcomes for health care, is headquartered in London with offices in Europe and North America. It has a staff of approximately 100 scientists and consultants.
“Achieving regulatory approval alone no longer determines a drug’s or therapy’s commercial success, or even guarantees its market launch,” said Thomas Kerbusch, president of Certara Strategic Consulting Services. “Today, each product must be evaluated from a value perspective by payors and health authorities in order to be placed on the formulary, factored into reimbursement rates, and put into treatment plans before it is available for healthcare providers to prescribe. The addition of Analytica Laser will allow us to expand our science and technology decision-support system, factoring in HEOR and the crucial issue of real-world value from as early as Phase 1, through the product life cycle, to health technology assessment and payor decisions.”
Roman Casciano, general manager of Analytica Laser, said the company is pleased to join Certara.
“Our complementary approaches will allow us to integrate HEOR and real-world value assessments with pharmacometrics data – delivering safety, efficacy and effectiveness insights – and providing a unique market advantage for our customers,” Casciano said.
Casciano will lead Certara’s new market access, HEOR and real-world evidence group as senior vice president. Billy Amzal, current lead of decision analytics for Analytical Laser, will continue to serve in a senior management capacity as senior vice president, decision and real-world data analytics.
Analytica Laser Founder Lucien Abenhaim, will join Certara as a scientific advisor.
“I could not be more pleased that Analytica Laser will be joining the Certara family, continuing serving patient health through the application of insightful science,” Abenhaim said. “I am amazed by the many synergies between the organizations and foresee a very bright future for the company, its staff and our clients.”
Financial terms of the deal were not disclosed.